Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,818,480
  • Shares Outstanding, K 1,246,266
  • Annual Sales, $ 27,116 M
  • Annual Income, $ 5,665 M
  • EBIT $ 823 M
  • EBITDA $ 3,516 M
  • 60-Month Beta 0.18
  • Price/Sales 4.29
  • Price/Cash Flow 10.44
  • Price/Book 6.32

Options Overview Details

View History
  • Implied Volatility 23.28% ( +0.59%)
  • Historical Volatility 28.28%
  • IV Percentile 58%
  • IV Rank 37.51%
  • IV High 33.98% on 08/05/24
  • IV Low 16.86% on 12/08/23
  • Put/Call Vol Ratio 0.35
  • Today's Volume 6,076
  • Volume Avg (30-Day) 12,224
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 247,743
  • Open Int (30-Day) 244,862

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.65
  • Number of Estimates 11
  • High Estimate 1.99
  • Low Estimate 1.13
  • Prior Year 1.72
  • Growth Rate Est. (year over year) -4.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
86.08 +7.03%
on 11/19/24
98.90 -6.85%
on 11/11/24
+0.44 (+0.48%)
since 11/06/24
3-Month
78.36 +17.57%
on 09/09/24
98.90 -6.85%
on 11/11/24
+13.41 (+17.04%)
since 09/06/24
52-Week
62.07 +48.43%
on 05/31/24
98.90 -6.85%
on 11/11/24
+12.77 (+16.09%)
since 12/06/23

Most Recent Stories

More News
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

Gilead Sciences has recently demonstrated strong performance, outperforming the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on its future.

XLV : 144.28 (-0.57%)
GILD : 92.13 (-1.35%)
AMGN : 272.58 (-0.64%)
Is Amgen Stock Underperforming the Dow?

Despite pharma giant Amgen trailing behind the Dow index over the past three months, analysts remain cautiously bullish about the stock's growth potential.

$DOWI : 44,642.52 (-0.28%)
GILD : 92.13 (-1.35%)
AMGN : 272.58 (-0.64%)
Insider Sale: Chief Financial Officer of $GILD (GILD) Sells 127,930 Shares

Andrew D Dickinson, the Chief Financial Officer of $GILD ($GILD), sold 127,930 shares of the company on 11-29-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

GILD : 92.13 (-1.35%)
Insider Sale: Chief Medical Officer of $GILD (GILD) Sells 3,199 Shares

Merdad Parsey, the Chief Medical Officer of $GILD ($GILD), sold 3,199 shares of the company on 11-27-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.4%...

GILD : 92.13 (-1.35%)
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?

Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It...

MRK : 103.09 (-0.44%)
GILD : 92.13 (-1.35%)
GSK : 34.57 (+0.12%)
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating

AbbVie’s ABBV shares rose 3.0% on Friday after Leerink Partners analyst, David Risinger, upgraded his rating on the stock from Market Perform to Outperform.Excluding Friday’s movement, AbbVie stock...

GILD : 92.13 (-1.35%)
ABBV : 176.19 (+0.01%)
PFE : 25.73 (+0.12%)
1 ETF to Build a Wide Moat for Your Portfolio

The VanEck Vectors Morningstar Wide Moat ETF (MOAT) stands out as a strategic investment option, focusing on companies with sustainable competitive advantages and strong economic moats, making it a compelling...

MOAT : 98.42 (+0.37%)
ADSK : 307.71 (+0.83%)
EMR : 130.98 (-1.63%)
GILD : 92.13 (-1.35%)
CRM : 361.99 (+0.17%)
BMY : 59.38 (+0.92%)
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

Novartis NVS announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with...

NVS : 101.99 (-0.52%)
GILD : 92.13 (-1.35%)
PFE : 25.73 (+0.12%)
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license application (sBLA) seeking approval of Dupixent for the treatment of chronic spontaneous...

GILD : 92.13 (-1.35%)
REGN : 778.00 (+1.32%)
PFE : 25.73 (+0.12%)
SNY : 48.46 (-0.10%)
Five Top Heart Health Stocks to Buy Heading into 2025

Heart health statistics are startling. Not only is heart disease the leading cause of death in the United States, it also claims the life of one person every 33 seconds. Plus, the estimated global annual...

ABT : 115.60 (+0.01%)
BSX : 90.07 (-0.51%)
CRDL : 1.4400 (unch)
GILD : 92.13 (-1.35%)
MDT : 84.01 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 95.74
2nd Resistance Point 94.98
1st Resistance Point 93.56
Last Price 92.13
1st Support Level 91.37
2nd Support Level 90.60
3rd Support Level 89.18

See More

52-Week High 98.90
Last Price 92.13
Fibonacci 61.8% 84.83
Fibonacci 50% 80.49
Fibonacci 38.2% 76.14
52-Week Low 62.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar